APA (7th ed.) Citation

Reijneveld, J. C., Machingura, A., Coens, C., Taphoorn, M. J. B., Taal, W., Clement, P. M., . . . van den Bent, M. J. (2023). Health-related quality-of-life results from the randomised phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact first-recurrence World Health Organization grade 2 and 3 glioma (European Organization for Research and Treatment of Cancer 26091). European journal of cancer, 190, . https://doi.org/10.1016/j.ejca.2023.112946

Chicago Style (17th ed.) Citation

Reijneveld, Jaap C., et al. "Health-related Quality-of-life Results from the Randomised Phase II TAVAREC Trial on Temozolomide with or Without Bevacizumab in 1p/19q Intact First-recurrence World Health Organization grade 2 and 3 Glioma (European Organization for Research and Treatment of Cancer 26091)." European Journal of Cancer 190 (2023). https://doi.org/10.1016/j.ejca.2023.112946.

MLA (9th ed.) Citation

Reijneveld, Jaap C., et al. "Health-related Quality-of-life Results from the Randomised Phase II TAVAREC Trial on Temozolomide with or Without Bevacizumab in 1p/19q Intact First-recurrence World Health Organization grade 2 and 3 Glioma (European Organization for Research and Treatment of Cancer 26091)." European Journal of Cancer, vol. 190, 2023, https://doi.org/10.1016/j.ejca.2023.112946.